相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs
James D. Chambers et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2020)
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA
Giorgia Coratti et al.
NEUROMUSCULAR DISORDERS (2020)
Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden
Santiago Zuluaga-Sanchez et al.
PHARMACOECONOMICS (2019)
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Darryl C. De Vivo et al.
NEUROMUSCULAR DISORDERS (2019)
Outrageous prices of orphan drugs: a call for collaboration
Lucio Luzzatto et al.
LANCET (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Priority-setting in healthcare: a framework for reasonable clinical judgements
K. Baeroe
JOURNAL OF MEDICAL ETHICS (2009)
Assessing the economic challenges posed by orphan drugs
Michael F. Drummond et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2007)
Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness
UH Graneheim et al.
NURSE EDUCATION TODAY (2004)
分享论文
